Australia
Yesterday, top-line data from Bionomics Limited revealed details of the biopharmaceutical company’s Phase II clinical trial of BNC210 in regards to patients with post traumatic stress disorder.
Trial did not meet primary endpoint of decrease in PTSD symptoms as measured by CAPS-5 at 12 weeks
Rhinomed signs 12-year exclusive licensing agreement with New York based Columbia Care LLC, the largest and most experienced manufacturer and provider of medical cannabis products and services in the United States.
MMJ PhytoTech Ltd (ASX:MMJ) (OTCMKTS:MMJJF) provides the Company’s Annual Report to shareholders.
Cynata Therapeutics Limited is pleased to announce data from a preclinical model demonstrating that its proprietary Cymerus™ mesenchymal stem cells (MSCs) significantly ameliorate the effects of cytokine release syndrome (CRS), a potentially severe and life-threatening adverse reaction to cancer immunotherapy.
Alliance for medicinal chemistry optimization and development of novel checkpoint blockade approach
DEP® irinotecan outperforms in pancreatic cancer model
Imugene Limited today announced the Phase 1b clinical trial of its HER-Vaxx cancer vaccine in HER-2 gastric cancer patients had completed recruitment.
MMJ PhytoTech Limited attaches a copy of a news release by the Ontario Cannabis Store (“OCS”) confirming that it has entered into recreational cannabis supply agreements with a number of producers, including United Greeneries, a subsidiary of Harvest One Cannabis Inc.
Regeneus Ltd today reported that it has received $2.4m from the Australian Government’s Research and Development tax incentive program for activities conducted during the financial year 2018.
PRESS RELEASES